Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,387 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Diagnostic Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Interventions
Social media recruitment, Self-Assessment, Follow-up
Behavioral
Lead sponsor
ZS Associates
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Cancer Diagnosis, Non-Metastatic Neoplasm, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Depression, Anxiety, Desmoid
Interventions
Promoting Resilience in Stress Management Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brighton, Massachusetts
Conditions
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Self blood glucose monitoring and insulin administration, Standard care
Procedure
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more
Conditions
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination, Cystoscopy, Biopsy, Bone Scan, PSMA PET Scan, Multiparametric Magnetic Resonance Imaging
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
190
States / cities
Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more
Completed Not applicable Interventional Results available

OCT Pilot in Esophagus

NCT03434834
Conditions
Barrett Esophagus
Interventions
optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
Non-contrast Computed Tomography (CT) Scans (Metallic Markers), Non-contrast CT Scans (Metallic Markers)
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Conditions
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
Conditions
Ambulation Difficulty, Lower Extremity Problem
Interventions
Gigstride Ambulatory Device
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cancer, Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation
Interventions
magnetic resonance imaging, Serum ferritin
Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions
nfant feeding solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Nervous System Disease, Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years to 100 Years
Enrollment
3,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Completed No phase listed Observational Accepts healthy volunteers

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

NCT05144971
Conditions
Diabete Mellitus, CKD, ESRD
Interventions
Glucose, Creatinine
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Gardens, Florida
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

NCT06717334
Conditions
Lung Cancer Screening
Interventions
Low Dose CT imaging, blood draws, screening questionnaire
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more